Carcinogenesis and Chemoprevention

致癌与化学预防

• 批准号: 10333246
• 负责人: Frank G. Ondrey
• 金额: $ 4.85万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-01 至 2024-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10333246
• 关键词: Address; Agriculture; Analytical Biochemistry; Area; Award; Basic Science; Biochemical Pathway; Biological Markers; Biological Sciences; Biometry; Budgets; Cancer Burden; Cancer Center; Cancer Center Support Grant; Carcinogen exposure; Carcinogenesis Mechanism; Catchment Area; Categories; Chemicals; Chemoprevention; Chest; Clinical Chemoprevention; Clinical Research; Clinical Trials; Clinical Trials Network; Collaborations; Comparative Pathology; Cutaneous; Data; Development; Direct Costs; Doctor of Philosophy; Eligibility Determination; Engineering; Environment; Environmental Health; Evolution; Faculty; Family; Flow Cytometry Shared Resource; Focus Groups; Food; Funding; Future; Ginger; Goals; Group Meetings; Growth; Head and Neck Surgeon; Head and neck structure; Healthcare; Human; Individual; Institutes; Institution; Intervention; Knowledge; Lead; Leadership; Malignant Neoplasms; Medicine; Minnesota; Minority Groups; Molecular; National Cancer Institute; Natural Resources; Organ; Otolaryngologist; Otolaryngology; Paper; Patients; Peer Review; Pharmacy facility; Pilot Projects; Population; Populations at Risk; Prevention strategy; Prostate; Public Health; Public Health Schools; Public Policy; Publications; Publishing; Request for Proposals; Research; Research Personnel; Research Project Grants; Research Support; Resource Sharing; Resources; Risk; Running; Schools; Science; Scientist; Screening for cancer; Shapes; Site; Smoker; Source; Strategic Planning; Structure; Techniques; Tobacco; Tobacco use; Tobacco-Related Carcinoma; Translating; Translations; United States National Institutes of Health; Universities; Veterinary Medicine; Work; base; burden of illness; cancer biomarkers; cancer chemoprevention; cancer clinical trial; cancer genomics; cancer prevention; cancer risk; carcinogenesis; chemical carcinogenesis; cohort; college; dietary; epidemiology study; experience; medical schools; meetings; member; mid-career faculty; novel; personalized medicine; pre-clinical; preclinical study; prevent; professor; programs; recruit; risk stratification; smoking cessation; specific biomarkers; synergism; tobacco regulation; urologic; working group

Carcinogenesis and Chemoprevention Program Summary The scientific goals of the Carcinogenesis and Chemoprevention Program are to identify biomarkers for tobacco-related cancer risk; and to understand how environmental and dietary chemicals contribute to carcinogenesis through specific biochemical pathways and to apply this knowledge for individualized cancer risk stratification and cancer prevention. The ultimate objective is to translate these findings into investigator- initiated clinical trials that change public policy and health care. To achieve our goals, we have successful, mature research programs which address the following aims: 1) to characterize the harmful effects of tobacco chemicals and products and develop biomarkers for cancer risk stratification in clinical and epidemiological studies; 2) to understand how chemicals in food and medicine and specific biochemical pathways may contribute to carcinogenesis; 3) to identify food products, as well as natural and synthetic chemicals, that reduce cancer risk. Drs. Lisa Peterson and Frank Ondrey lead the Program, which has 24 members, representing 14 departments and 8 schools or colleges (College of Biological Sciences; College of Food, Agriculture and Natural Resources; College of Pharmacy; College of Science and Engineering; College of Veterinary Medicine; Hormel Institute; Medical School, and School of Public Health). In the last budget year, these members were supported by $5.6 million in direct costs from the National Cancer Institute; funding from all peer-reviewed sources totaled $8.2 million in direct costs. Since 2013, Program members have published 628 papers, 20% of which resulted from intraprogrammatic collaborations, 20% from interprogrammatic collaborations, and 87% from external collaborations. Since 2013, 53 clinical trials in all clinical research categories have opened under this programmatic area and have accrued 7728 subjects. The Masonic Cancer Center (MCC) has provided substantial value to the program, including access to shared resources, recruiting 3 new faculty, funding of 10 pilot projects ($382,500 awarded), 1 research retreat, 1 strategic planning meeting, 24 meetings on recent Program member research projects, 2 special seminars, and 2 meetings to discuss specific requests for proposals from the NIH. A monthly interprogrammatic translational biomarker focus group brings together population scientists and clinicians with basic research groups developing specific biomarkers. The Program's future direction fits well within the MCC's strategic plan. We will continue the translation of our basic research into chemoprevention clinical trials (Scientific Priority for Growth 3- SPG3). We are actively using biomarkers to understand carcinogenesis and to develop strategies to personalize cancer screening and treatments (SPG4). Program members are actively involved in the planning of the 10,000 Family cohort (SPG5), and this resource will be invaluable for the translation of our science to the catchment area. Lastly, we plan to use tobacco-related biomarkers to develop individually targeted smoking cessation and screening protocols in Minnesota's minority populations who have a disproportionate cancer burden (SPG6).

致癌和化学预防计划摘要 致癌作用和化学预防计划的科学目标是确定生物标志物， 烟草相关的癌症风险;并了解环境和饮食化学品如何有助于 通过特定的生物化学途径致癌，并将这些知识应用于个体化癌症 风险分层和癌症预防。最终目标是将这些发现转化为研究者- 发起了改变公共政策和医疗保健的临床试验。为了实现我们的目标，我们取得了成功， 成熟的研究计划，其目的是：1）描述烟草的有害影响 化学品和产品，并制定生物标志物，用于临床和流行病学中的癌症风险分层 研究; 2）了解食品和药物中的化学物质以及特定的生化途径如何 有助于致癌作用; 3）确定食品，以及天然和合成化学品， 降低癌症风险。丽莎彼得森博士和弗兰克奥恩蒂博士领导该项目，该项目有24名成员， 代表14个部门和8所学校或学院（生物科学学院;食品学院， 农业与自然资源学院;药学院;科学与工程学院; 兽医学;荷美尔研究所;医学院和公共卫生学院）。在上一个预算年度， 这些成员得到了国家癌症研究所560万美元的直接费用支持; 所有经同行审查的来源的直接费用共计820万美元。自2013年以来，该计划的成员已经出版了 628篇论文，其中20%来自项目内合作，20%来自项目间合作 87%来自外部合作。自2013年以来，所有临床研究中有53项临床试验 在这一方案领域下开设了各种类别，并积累了7 728个主题。共济会癌症 中心（MCC）为该计划提供了实质性的价值，包括获得共享资源，招募 3名新教师，资助10个试点项目（382，500美元），1次研究务虚会，1次战略规划会议， 24次近期项目成员研究项目会议，2次专题研讨会，2次讨论会 NIH的具体提案要求。每月一次的跨项目翻译生物标志物焦点小组 汇集了人口科学家和临床医生与基础研究小组开发特定的生物标志物。 该方案的未来方向完全符合千年挑战中心的战略计划。我们将继续翻译我们的 化学预防临床试验的基础研究（科学优先增长3-SPG 3）。我们正在积极 使用生物标志物来了解致癌作用，并制定个性化癌症筛查策略， 治疗（SPG 4）。计划成员积极参与10，000个家庭队列的规划 （SPG 5），这个资源将是非常宝贵的翻译我们的科学集水区。最后我们 计划使用烟草相关的生物标志物来开发针对个人的戒烟和筛查 明尼苏达州的少数民族人口谁有不成比例的癌症负担（SPG 6）的协议。